期刊文献+

3,4-二氢喹啉-2(1H)-酮衍生物的设计合成及抗精神分裂活性研究 被引量:3

Design,synthesis and anti-schizophrenia activity of 3,4-dihydroquinolin-2(1H)-one derivatives
原文传递
导出
摘要 目的设计合成3,4-二氢喹啉-2(1H)-酮类化合物,考察其对D2、5-HT2A、5-HT1A受体的亲和力,并对代表化合物进行体内抗精神分裂活性测试。方法 7-羟基-3,4-二氢喹啉-2(1H)-酮与二卤代烷进行O-烷基化反应,再与相应的哌啶衍生物反应得到目标产物(Ⅰ1~Ⅰ11);对目标化合物进行了D2、5-HT2A、5-HT1A受体亲和力初步试验,并选择化合物Ⅰ7进行体内抗阿朴吗啡诱导的小鼠精神分裂模型实验。结果与结论共合成了11个新化合物,其结构经质谱及核磁共振氢谱确证。其中化合物Ⅰ7体内外活性良好,具有进一步研究的价值。 7-Aminoalkyloxy-3,4-dihydroquinolin-2(1H)-ones have D2 receptor affinity,and aromatic heterocyclic piperidines or piperazines have 5-HT2A and 5-HT1A affinity,These two fragments were introduced to one structure,with a public nitrogen atom.Eleven new 3,4-dihydroquinolin-2(1H)-one derivatives were designed and synthesized.This new serial compounds were prepared by the following method:7-hydroxyl-3,4-dihydroquinolin-2(1H)-one was reacted with dihalides as O-alkylation reaction to yield Ⅲ,and then the target compounds were prepared by Ⅲ and corresponding piperidine derivatives(Ⅰ1-Ⅰ11).The in vitro activities to D2,5-HT2A,5-HT1A receptors were tested for target compounds,their binding affinities to D2 and 5-HT1A are about 1-100 nmol · L-1,and to 5-HT2A are about 1-10 nmol · L-1.Their in vivo activity of apomorphine-induced stereotype in mice for representative compound Ⅰ7 were also tested,and it showed high inhibitory rate(70.23%) at 0.35 mg · kg-1(p.o.).Preliminary SAR indicates:The chain in the middle with three or four carbon atoms gives better activities to D2 and 5-HT2A,3-(piperazin-1-yl)benzo[d]isothiazole is more beneficial for 5-HT1A activity than 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole.
出处 《中国药物化学杂志》 CAS CSCD 2011年第2期81-87,共7页 Chinese Journal of Medicinal Chemistry
基金 国家十一五"重大新药创制"资助项目(2009ZX09103-048)
关键词 3 4-二氢喹啉-2(1H)-酮 抗精神分裂 合成 3 4-dihydroquinolin-2(1H)-one anti-schizophrenia synthesis
  • 相关文献

参考文献8

  • 1MIYAMOTO S, DUNCAN G, MARX C, et al. Treat- ments for schizophrenia:a critical review of pharma- cology and mechanisms of action of antipsychotic drugs[J]. Mol Psychiatry ,2004,10( 1 ) :79 - 104.
  • 2朱玉莹,胡春.伊潘立酮(iloperidone)[J].中国药物化学杂志,2009,19(5):400-400. 被引量:17
  • 3KECK J P, MCELROY S. Aripiprazole: a partial do- pamine D2 receptor agonist anfipsychotic [ J ]. Expert Opin Invest Drugs, 2003,12 (4) : 655 - 662.
  • 4NEWMAN-TANCREDI A. The importance of 5- HTIA receptor agonism in antipsychotic drug action: rationale and perspectives [J]. Curr Opin Investig Drugs,2010,11 ( 7 ) : 802.
  • 5COLE P, SERRADELL N, ROSA E ,et al. Lurasidone hydrochloride [J].Drugs Future, 2008,33 ( 4 ) : 316 - 322.
  • 6MORPHY R, RANKOVIC Z. Designed multiple lig- ands. An emerging drug discovery paradigm [ J ]. J Med Chem ,2005,48(21 ) :6523 - 6543.
  • 7LAWLER C, PRIOLEAU C, LEWIS M, et al. Interac- tions of the novel antipsychotic aripiprazole (OPC- 14597 ) with dopamine and serotonin receptor sub-types [ J ]. Neuropsychopharmacology, 1999,20 ( 6 ) : 612 -627.
  • 8PROTAIS P, COSTENTIN J, SCHWARTZ J. Climbing behavior induced by apomorphine in mice:a sim- ple test for the study of dopamine receptors in striatum [J]. Psychopharmacology ( Berlin, Ger. ), 1976, 50(1) :1 -6.

二级参考文献3

  • 1US FDA. Fanapt[ EB/OL]. [ 2009 - 05 - 06 ]. http ://www. fda. gov/bbs/topics/NEWS/2009/NEW02009, html.
  • 2JOSEPH T,RICHARD C,BLAINE L. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl) - 1,2- benzisoxazoles[ J]. J Med Chem,1985,2g(6) :761 -769.
  • 3US FDA. Full preseribing information for Fanapt[ EB/OL]. [ 2009 - 05 - 06 ]. http ://www. accessdata, fda. gov/drugsatfda_docs/label/2009/0221921b1. pdf.

共引文献16

同被引文献60

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部